Lesson
Recognize a Multisystem Disease
SLE is not one rash, one antibody, or one laboratory result. It is a heterogeneous autoimmune disease whose active manifestations, dangerous mimics, and accumulated damage must be mapped across the whole patient.
- Multisystem phenotype
- ANA entry criterion
- Weighted domains
- Flare versus infection
- Drug-induced lupus
Connect skin, joints, blood, kidney, nervous system, lungs, heart, and vessels.
Use serology, complement, urine, imaging, and examination to strengthen clinical judgment.
Evaluate infection, toxicity, thrombosis, malignancy, and fixed damage beside the flare.
Map the phenotype
Inflammatory skin, joint, blood, kidney, cardiopulmonary, vascular, and nervous-system findings can appear together or over time. New edema, neurologic change, bleeding, dyspnea, chest pain, or hemodynamic instability changes urgency.
Use criteria without surrendering judgment
The 2019 EULAR and ACR classification system requires positive ANA as an entry criterion, then uses weighted clinical and immunologic domains. It was built for consistent classification and does not turn ANA positivity into a diagnosis.
Run flare and mimic in parallel
Fever, fatigue, cytopenias, organ dysfunction, and inflammatory markers may reflect active SLE, infection, medication toxicity, thrombosis, malignancy, or overlap disease. Unstable patients require immediate treatment of dangerous possibilities while the cause is clarified.
Recognize a drug relationship
Procainamide, hydralazine, isoniazid, minocycline, quinidine, selected antithyroid drugs, and some biologics can produce drug-induced lupus. Review timing, phenotype, organ involvement, autoantibodies, and improvement after withdrawal rather than using a memorized list alone.
Quick check
Lesson
Trace the Immune Architecture
SLE emerges from interacting susceptibility, cellular debris, nucleic-acid sensing, type I interferon, autoreactive B cells, autoantibodies, complement, and tissue-specific injury. That network explains why no single marker or target describes every patient.
- Immune tolerance
- Nucleic-acid sensing
- Type I interferon
- BLyS
- Immune complexes
Innate sensing amplifies type I interferon programs and inflammatory gene expression.
Autoreactive B cells persist, differentiate, and contribute to autoantibody production.
Complement activation and local inflammation translate systemic autoimmunity into organ damage.
Lose tolerance
Genetic, epigenetic, hormonal, infectious, and environmental factors can alter immune tolerance and clearance of apoptotic material. Exposed nuclear antigens then become part of a self-sustaining innate and adaptive immune response.
Amplify interferon
Nucleic-acid sensing can activate type I interferon programs and inflammatory gene expression. Anifrolumab binds IFNAR1, inhibits type I interferon signaling, and reduces available receptor at the cell surface.
Sustain autoreactive B cells
BLyS supports B-cell survival and differentiation. Belimumab binds soluble BLyS and reduces survival signaling, while anti-CD20 therapies deplete a B-cell lineage more directly. These are related but distinct strategies.
Deposit immune complexes
Autoantibody-containing immune complexes can activate complement and inflame tissue. Complement and anti-dsDNA trends may support assessment, but organ findings, urine, examination, and function determine whether treatment should change.
Quick check
Lesson
Treat Activity Before It Becomes Damage
Current care aims for remission or low disease activity, early control of organ-threatening inflammation, reduced glucocorticoid exposure, and deliberate prevention of irreversible disease and treatment damage.
- Activity
- Damage
- Organ priority
- Prednisone taper
- Escalation
Name the organ, severity, dangerous alternative, and immediate treatment target.
Use early steroid-sparing therapy and taper glucocorticoids as control becomes durable.
Do not intensify immunosuppression for fixed injury or a noninflammatory symptom pattern.
Prioritize irreversible risk
When several organs are active, therapy should cover the full flare but prioritize the manifestation most likely to threaten life or permanent function. Severe neurologic, renal, hematologic, vasculitic, pulmonary, and cardiac disease can require urgent combination therapy.
Measure activity and damage separately
Assess disease activity regularly, especially when clinical status or SLE-directed therapy changes. Assess accumulated damage at least annually. Chronic pain, avascular necrosis, scarring, neuropathy, or fatigue may not improve with more immunosuppression.
Use glucocorticoids as a bridge
For organ-threatening flares, pulse methylprednisolone may precede an oral taper. Once stable and controlled, current ACR guidance strongly recommends reaching prednisone 5 mg daily or less, ideally zero, within six months when feasible.
Escalate refractory inflammation
Confirm diagnosis, actual medication exposure, dose, duration, access, and competing explanations. If active disease remains refractory, change or add an organ-appropriate conventional or biologic immunosuppressive therapy rather than preserving an ineffective plan.
Quick check
Lesson
Make Hydroxychloroquine a Complete Safety System
Hydroxychloroquine is foundation therapy for most people with SLE, including during sustained remission. Its value depends on durable access, correct exposure, eye surveillance, and recognition of cardiac, metabolic, neuromuscular, and skin toxicity.
- Routine therapy
- Long-term continuation
- 5 mg/kg
- Retinal screening
- Systemic toxicity
Keep the long-term average at 5 mg/kg per day or less unless a deliberate exception is justified.
Match eye follow-up to dose, duration, kidney function, tamoxifen, and macular risk.
Investigate new conduction disease, cardiomyopathy, hypoglycemia, weakness, rash, or blood abnormalities.
Use it routinely
The 2025 ACR guideline strongly recommends hydroxychloroquine unless contraindicated and conditionally recommends indefinite continuation even during sustained remission. Do not remove the foundation automatically because symptoms are quiet.
Calculate long-term exposure
Use actual body weight and target a long-term average daily dose of 5 mg/kg or less. A 68 kg adult has a 340 mg daily ceiling by this target. Because tablets are fixed strengths, clinicians may use a practical weekly schedule that preserves the average rather than rounding upward without review.
Protect vision
Obtain a baseline eye evaluation and use annual surveillance according to dose, duration, kidney function, tamoxifen exposure, macular disease, and retinal pattern. Retinal change can progress after discontinuation, so suspected toxicity requires prompt ophthalmic evaluation.
Look beyond the retina
Cardiomyopathy, conduction disease, QT prolongation, hypoglycemia, neuromyopathy, severe skin reactions, and blood disorders are clinically important. New syncope, block, proximal weakness, severe rash, or unexplained hypoglycemia deserves urgent review.
Quick check
Lesson
Match Therapy to the Active Organ
Nonrenal SLE spans cutaneous, musculoskeletal, serosal, hematologic, neurologic, cardiac, pulmonary, and vascular disease. The therapy must fit the organ, severity, exclusions, and speed of injury.
- Cutaneous lupus
- Inflammatory arthritis
- Serositis
- Cytopenias
- Neurocardiopulmonary disease
Build from photoprotection and hydroxychloroquine toward durable steroid-sparing control.
Grade urgency, exclude competing causes, and match treatment to bleeding or physiologic risk.
Treat inflammatory emergencies in combination while evaluating infection, ischemia, embolism, and damage.
Treat skin with a ladder
Photoprotection, hydroxychloroquine, and site-appropriate topical glucocorticoid or calcineurin inhibitor form the base. Persistent moderate or severe disease can justify methotrexate, a mycophenolic acid analog, anifrolumab, or belimumab rather than repeated systemic-steroid bursts.
Build durable joint and serosal control
Short NSAID or limited glucocorticoid use may bridge inflammatory arthritis. Persistent arthritis on hydroxychloroquine can require methotrexate, azathioprine, mycophenolic acid analog, belimumab, or anifrolumab. Pleuropericarditis requires exclusion of infection, ischemia, embolism, and tamponade before an SLE label is accepted.
Grade hematologic urgency
Asymptomatic leukopenia without other activity may not require immunosuppression. Active bleeding from severe thrombocytopenia or unstable autoimmune hemolysis can require glucocorticoid plus IVIG and or anti-CD20 therapy rather than observation.
Treat inflammatory emergencies in combination
Myelitis, optic neuritis, acute confusional state, vasculitis, diffuse alveolar hemorrhage, myocarditis, and selected seizures need immediate specialist evaluation. Symptom control alone does not treat the inflammatory driver.
Quick check
Lesson
Choose Conventional Immunosuppression by Organ and Risk
Methotrexate, azathioprine, mycophenolic acid analogs, calcineurin inhibitors, and cyclophosphamide are not interchangeable. Their role follows organ involvement, severity, prior response, toxicity, interactions, and reproductive plans.
- Methotrexate
- Azathioprine
- Mycophenolate
- Calcineurin inhibitors
- Cyclophosphamide
Match the active organ, monitoring burden, interactions, and reproductive plan.
Use organ-specific evidence and follow blood, kidney, pressure, infection, and exposure.
Balance urgent disease control against marrow, bladder, malignancy, gonadal, and cumulative toxicity.
Fit the lower-risk organ
Methotrexate can support inflammatory arthritis and selected skin disease. Azathioprine can serve several nonrenal and maintenance roles and may fit pregnancy planning better than methotrexate or mycophenolate, but blood, liver, thiopurine, and interaction risks remain.
Use mycophenolate deliberately
Mycophenolate suppresses lymphocyte purine synthesis and is central to many nephritis and organ-threatening strategies. Monitor blood counts, infection, gastrointestinal effects, organ function, interactions, and reproductive risk.
Reserve cyclophosphamide for the right severity
Cyclophosphamide can be life-saving in selected severe renal, neurologic, vasculitic, or cardiopulmonary disease. Infection, marrow, bladder, malignancy, cumulative-dose, and gonadal toxicity require protocolized prevention and monitoring.
Reconcile every transition
Allopurinol or febuxostat can markedly alter azathioprine exposure. Kidney function changes mycophenolate and calcineurin-inhibitor context. Pregnancy plans can require a disease-stable transition long before conception.
Quick check
Lesson
Use Biologic Targets Without Blurring Their Boundaries
Belimumab, anifrolumab, and CD20-directed therapies act at different points in B-cell and interferon biology. Current indications, age limits, organ exclusions, routes, and safety plans determine how each fits.
- Belimumab
- BLyS
- Anifrolumab
- IFNAR1
- Anti-CD20
Reduce soluble B-cell survival signaling within its labeled age, route, and organ boundaries.
Block type I interferon signaling for appropriate adult nonrenal disease.
Separate guideline use from current FDA indications and preserve infusion, infection, and hepatitis planning.
Inhibit BLyS
Belimumab is labeled with standard therapy for active SLE and active lupus nephritis in patients five years and older. Adult IV dosing is 10 mg/kg on days 0, 14, and 28, then every 28 days. Adult subcutaneous SLE dosing is 200 mg weekly; nephritis begins with a label-specific loading schedule.
Block IFNAR1
Anifrolumab is labeled for adults with moderate to severe SLE receiving standard therapy. The April 2026 label offers IV 300 mg every four weeks or subcutaneous 120 mg weekly. It is not recommended for severe active lupus nephritis or severe active CNS lupus.
Deplete CD20-positive cells
Rituximab is used in selected guideline scenarios but does not have a general SLE indication. Obinutuzumab now has a current adult active lupus nephritis indication with standard therapy. Both require infusion and hepatitis B planning.
Preserve one rationale
Avoid routine dual-biologic therapy. Screen and respond to infection, update indicated vaccines, review hypersensitivity and malignancy context, and document the exact organ target and expected response.
Quick check
Lesson
Detect and Treat Lupus Nephritis Early
Kidney injury can be clinically quiet until proteinuria, active sediment, hypertension, or declining function becomes visible. Contemporary care screens earlier, biopsies at a lower threshold, and often combines therapies from the start.
- Proteinuria screening
- Kidney biopsy
- Class III and IV
- Class V
- Triple therapy
Look even when symptoms are quiet and accelerate evaluation during extra-renal activity.
Distinguish active, chronic, proliferative, and membranous injury before choosing a regimen.
Use proteinuria, kidney function, pressure, urine sediment, exposure, and toxicity to judge response.
Screen before symptoms
In SLE without known kidney disease, quantify urine protein at least every six to twelve months and during extra-renal flares. New urine abnormalities, hypertension, edema, or kidney dysfunction require faster evaluation.
Use biopsy to direct treatment
Current ACR guidance conditionally recommends biopsy when urine protein exceeds 0.5 g/g and or kidney function is impaired without another explanation. Histology separates active, chronic, proliferative, and membranous patterns that require different strategies.
Build contemporary combination therapy
For active class III or IV nephritis, current options pair glucocorticoid with mycophenolate plus belimumab, mycophenolate plus a calcineurin inhibitor, or low-dose cyclophosphamide plus belimumab. Pure class V disease with proteinuria above 1 g/g favors glucocorticoid, mycophenolate, and calcineurin inhibition.
Monitor response and toxicity
Quantify proteinuria at least every three months until complete response, then every three to six months during sustained response. Track kidney function, urine sediment, blood pressure, adherence, infection, marrow, and product-specific toxicity. Voclosporin requires close eGFR, potassium, pressure, neurologic, QT, and interaction review.
Quick check
Lesson
Protect the Future Treatment Must Preserve
SLE outcomes reflect disease, treatment, infection, cardiovascular and bone risk, mental health, reproductive goals, and antiphospholipid antibodies. Prevention is part of immunosuppressive therapy, not an optional appendix.
- Vaccination
- Infection
- Cardiovascular risk
- Pregnancy planning
- Antiphospholipid antibodies
Coordinate non-live vaccines, selected medication timing, exposure screening, and an infection plan.
Reduce glucocorticoid burden and address pressure, lipids, tobacco, diabetes, activity, and screening.
Make medication transitions, antibody context, fertility, contraception, and pregnancy goals visible before conception.
Vaccinate with timing
Give indicated non-live vaccines and coordinate selected medication timing. Live-vaccine timing depends on the immunosuppressive regimen. Anifrolumab increases herpes zoster risk, making recombinant zoster vaccination especially relevant when indicated.
Reduce cumulative harm
Address tobacco, blood pressure, lipids, diabetes, bone health, malignancy screening, infection risk, mood, sleep, activity, and glucocorticoid exposure. Controlled inflammation does not erase preventable comorbidity.
Plan pregnancy before exposure changes
Pregnancy outcomes improve when conception occurs during stable low activity on compatible therapy. Review mycophenolate, methotrexate, cyclophosphamide, renin-angiotensin drugs, anti-Ro and anti-La antibodies, thrombosis risk, contraception, fertility preservation, and pregnancy-compatible transitions before conception.
Interpret antiphospholipid antibodies in context
Persistent high-risk antibodies and a thrombotic or obstetric history can define antiphospholipid syndrome and change anticoagulation, estrogen, pregnancy, and procedural decisions. An isolated positive result is not automatically APS.
Quick check
Lesson
Make the Lupus Timeline Authoritative
Long-term SLE care depends on a visible record of organ history, activity, damage, therapy exposure, adherence, toxicity, screening, vaccines, reproductive planning, access, and the next decision.
- Remission
- Immunosuppressive taper
- Flare plan
- Handoff
- Access
Capture prior responses, toxicities, access failures, damage, and the reason for each change.
Document active exposure, disease activity, organ function, safety monitoring, and current holds.
State the target, taper or escalation trigger, urgent flare plan, and responsible clinician.
Taper only after durable control
After three to five years of sustained remission or low disease activity, a cautious immunosuppressive taper toward discontinuation can be considered. Hydroxychloroquine is generally continued. Change one element, preserve monitoring, and define rescue criteria.
Write the flare plan before the flare
Name early symptoms, urgent renal, neurologic, cardiopulmonary, hematologic, thrombotic, and infectious signals, the contact route, required tests, and who can change therapy. Leftover high-dose steroids are not a substitute for assessment.
Build the handoff
Document every organ ever involved, last disease-activity and damage assessment, exact weekly or infusion timing, current holds, previous failures and toxicities, kidney and blood trends, vaccine status, reproductive plan, and restart ownership.
Design for actual access
Transportation, infusion distance, insurance, language, medication supply, monitoring burden, and specialist availability shape whether an evidence-based plan reaches the patient. Choose a sustainable route and treat access failure as a system problem, not a character judgment.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 160 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- American College of Rheumatology. 2025 Guideline for the Treatment of Systemic Lupus Erythematosus.
- American College of Rheumatology. 2024 Guideline for Screening, Treatment, and Management of Lupus Nephritis.
- American College of Rheumatology. 2019 EULAR and ACR Classification Criteria for Systemic Lupus Erythematosus.
- American College of Rheumatology. 2020 Reproductive Health Guideline.
- Bass AR, et al. 2022 ACR Guideline for Vaccinations in Rheumatic and Musculoskeletal Diseases.
- DailyMed. Hydroxychloroquine Sulfate Tablets Prescribing Information.
- DailyMed. Benlysta Belimumab Prescribing Information.
- DailyMed. Saphnelo Anifrolumab Prescribing Information.
- DailyMed. Lupkynis Voclosporin Prescribing Information.
- DailyMed. Gazyva Obinutuzumab Prescribing Information.
- American College of Rheumatology. Lupus Patient Information.